Xiaobin Wu - 06 Mar 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
President and COO
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
06 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 20:12:00 UTC
Previous filing
19 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Xiaobin Wu filed Form 4 for BeOne Medicines Ltd. (ONC) on 10 Mar 2026."

Quick Takeaways

  • This page summarizes Xiaobin Wu's Form 4 filing for BeOne Medicines Ltd. (ONC).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Filing timestamp: 10 Mar 2026, 20:12.

What Changed

  • Previous filing in this sequence was filed on 19 Nov 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wu Xiaobin President and COO C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 10 Mar 2026 0001739452

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC Ordinary Shares Award +168,922 +17% $0.000000* 1,137,900 06 Mar 2026 Direct F1
transaction ONC Ordinary Shares Award +78,624 +6.9% $0.000000* 1,216,524 06 Mar 2026 Direct F2
holding ONC American Depositary Shares 12,365 06 Mar 2026 Direct F3
holding ONC American Depositary Shares 4,000 06 Mar 2026 By Wife F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
F2 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
F3 Each American Depositary Share represents 13 Ordinary Shares.

Sponsored